Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Simon Property Group Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Simon Property Group Inc trades at $200.57 (market cap $64.29B). The key difference: Simon Property Group Inc is far larger — about 7.2× Kymera Therapeutics Inc. Common Stock's market cap, and Simon Property Group Inc pays a 4.48% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Simon Property Group Inc for 100 Days on average.
| KYMR | SPG | |
|---|---|---|
Market Cap | $8.88B | $64.29B |
Volume | 1,028,790 | 1,236,199 |
Sector | Health | Real Estate |
52-Week High | $127.31 | $236.70 |
52-Week Low | $55.80 | $173.35 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $8.27B | $92.74B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Simon Property Group (SPG) trades at $200.65, down 0.38% with bearish technical signals. The REIT shows strong fundamentals with 2025 revenue of $6.36B, net income of $4.63B (72.7% margin), and attractive valuation at 14.16 P/E. Recent earnings show mixed results with Q2 2026 missing expectations. The company maintains strong leasing demand and recently launched Simon Media Network to monetize mall traffic.
SPG offers value with solid dividend yield and double-digit return potential, though faces headwinds from rising bond yields and $2B debt maturities in 2024. Analyst consensus at $218.45 target suggests 8.9% upside, supported by accelerating NOI growth and A-rated balance sheet strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
